The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Lifespot Health (LSH) has appointed Matthew Golden as CEO effective immediately
  • Matthew is a commercial healthcare professional with almost 20 years experience in the pharmaceutical industry both in Australia and overseas
  • He has worked with the likes of Medical Developments International where he drove the sales of the ‘Green Whistle’ used in pain relief
  • At Lifespot, Matthew will review the company’s telehealth and medical cannabis inhaler strategies, and define the timing of its Medihale clinical trial
  • Additionally, Rodney Harrington and Frank Cannavo will resume their respective roles of Non-Executive Chairman and Non-Executive Director
  • Lifespot is up 17.7 per cent on the back of this news with shares trading for six cents each

Lifespot Health (LSH) has appointed Matthew Golden as CEO effective immediately.

Matthew is a commercial healthcare professional with almost 20 years experience in the pharmaceutical industry both in Australia and overseas.

He has a Masters of Marketing and a Bachelor of Science, both from Monash University in Melbourne.

He primarily worked at Pfizer Pharmaceuticals and Medical Developments International where he drove the sales of pain management products such as Penthrox which is known as the ‘Green Whistle’ for pain relief.

At Lifespot, Matthew will review the company’s telehealth and medical cannabis inhaler strategies, and define the timing of its Medihale clinical trial.

Additionally, Rodney Harrington and Frank Cannavo will resume their respective roles of Non-Executive Chairman and Non-Executive Director.

Lifespot is up 17.7 per cent on the back of this news with shares trading for six cents each at 3:24 pm AEDT.

LSH by the numbers
More From The Market Herald

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…

Little Green Pharma’s strong half-year performance signals robust Cannabis growth in Europe and Australia

Little Green Pharma (ASX:LGP) released its half-yearly financial report, showing revenue from ordinary cannabis sales is…

4DMedical inks MOU with Philips to expand XV Technology sales in North America

4DMedical (ASX:4DX) has signed a MOU with Philips to expand sales opportunities for its XV Technology…